2.3 The blood supply chain

Australia’s blood supply consists of fresh, plasma-derived and recombinant products that are vital in the treatment and management of a diverse range of clinical conditions affecting thousands of Australians every day. Australia’s blood sector is funded jointly by the Australian and state and territory governments, with contributions of 63% and 37%, respectively. In 2007–08, governments provided the NBA with $720.6 million to procure and manage Australia’s blood supply (see Table 2.2). Since the establishment of the NBA, governments have spent $2934.7 million on blood and blood-related products.

Table 2.2 Government provided funding to procure and manage the blood supply

Year Amount
($ million)
Growth (%)
2003–04 460.5
2004–05 536.8 16.6%
2005–06 577.4 7.6%
2006–07 639.4 10.8%
2007–08 720.6 12.7%
Total 2934.7 (average) 11.9%

The following pages outline the roles and responsibilities of the key stakeholders involved in the Australian blood supply chain as set out in Figure 2.1.

Australian, state and territory governments

As signatories to the National Blood Agreement, all governments are responsible for:

Therapeutic Goods Administration

The Therapeutic Goods Administration (TGA) is the regulator for blood and blood-related products in Australia. The TGA is responsible for:

Figure 2.1 Australian blood supply chain

Figure 2.1 Australian blood supply chain

Suppliers of blood and blood-related products

The NBA contracts with a number of suppliers of blood and blood-related products, including:

Contracts with suppliers for the provision of blood and blood-related products under standing offer arrangements include:

A standing offer is not a contract but a continuing offer by a supplier or suppliers to provide specified goods and services for a predetermined length of time, usually at a predetermined price. No contract is made until an order is placed which invokes the terms and conditions of the standing offer.

Back to top

< Previous | Contents | Next >